脂肪细胞型脂肪酸结合蛋白在ACS患者血浆中水平升高

孙艳转; 王宏伟; 乔增勇

doi:10.13201/j.issn.1001-1439.2021.11.014

脂肪细胞型脂肪酸结合蛋白在ACS患者血浆中水平升高

- 上海市奉贤区中心医院心内科(上海, 200333)
基金项目:
奉贤区科技发展基金(No:20201615)

详细信息

通讯作者: 王宏伟,E-mail:wanghongwei5322287@163.com

中图分类号: R541.4

收稿日期: 2021-07-29

Fatty acid binding protein 4 in patients with acute coronary syndrome

- Department of Cardiology, Central Hospital of Fengxian District in Shanghai, Shanghai, 200333, China

More Information

Corresponding author: WANG Hongwei, E-mail: wanghongwei5322287@163.com

Received Date: 29 July 2021

摘要

摘要: 目的:探寻急性冠状动脉综合征(ACS)及斑块不稳定新的生物标志物。方法:入组心内科或急诊科就诊的患者80例,年龄47~91岁,分为ACS组40例(男20例,女20例)及非ACS组40例(男18例,女22例),通过免疫抗体法滴定血浆中脂肪细胞型脂肪酸结合蛋白(FABP4)含量,同时收集入组患者的病史资料,分析比较两组FABP4水平差异。结果:与非ACS组比较,ACS组中年龄更高,C反应蛋白(CRP)、肌酸激酶同工酶(CK-MB)、肌红蛋白、肌酸激酶、糖化血红蛋白、FABP4增高,射血分数下降;相关分析显示血浆FABP4表达与是否存在ACS、肌钙蛋白I(TnI)、B型利钠肽(BNP)及女性独立相关。结论:ACS患者血浆FABP4表达水平升高,且这种升高独立于CRP、尿素氮、心血管病危险因素等,女性血浆FABP4水平高于男性,提示周围血中FABP4水平可能成为斑块不稳定性、ACS新的生物学标记物。
- 脂肪细胞型脂肪酸结合蛋白 /
- 急性冠状动脉综合征 /
- 不稳定斑块
Abstract: Objective: To provide new ideas and theoretical basis for the prevention and treatment of acute coronary syndrome(ACS).Methods: The 80 patients who were in hospital were involved, age from 47 to 91 years old. They were grouped: ACS group 40 examples(male 20, female 20) and control group 40 examples(male 18, female 22). The FABP4(fatty-acid binding protein) was measured by ELISA. At the same time, examples' clinical messages were collected. We compared the difference in plasma FABP4 and clinical messages.Results: Compared with the health group, the age, CRP, CK-MB mass, myoglobin, creatine kinase, glycosylated hemoglobin and FABP4 were higher and ejection fraction was decreased in ACS group. Correlation analysis showed that the expression of plasma FABP4 was independently correlation with the presence of ACS, troponin I, B-type natriuretic peptide and woman.Conclusion: Serum FABP4 levels increased in patients with ACS, and this elevated FABP4 levels is independent of CRP, urea nitrogen. FABP4 levels may be a new biomarker of peripheral blood in plaque instability and acute coronary syndrome.
- fatty acid binding protein 4 /
- acute coronary syndrome /
- rupture plague

HTML全文

参考文献(29)

[1]	Krusinov E,Peliknov T.Fatty acid binding proteins inadipose tissue:apromising link between metabolic syndrome and atherosclerosis[J].Diabetes Res Clin Pract,2008,82:S127-S134.
[2]	Koh JH,Shin YG,Nam SM,et al.Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2diabetic patients[J].Diabetes Care,2009,32(1):147-152.
[3]	Yeung DC,Xu A,Cheung CW,et al.Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis[J].Arterioscler Thromb Vasc Biol,2007,27(8):1796-1802.
[4]	Furuhashi M,Fuseya T,Murata M,et al.Local production of fatty acid-binding protein 4in epicardial/perivascular fat and macrophages is linked to coronary atherosclerosis[J].Arterioscler Thromb Vasc Biol,2016,26:825-834,836.
[5]	Xu A,Wang Y,Xu JY,et al.Adipocyte fatty acidbinding protein is a plasma biomarker closely associated with obesity and metabolic syndrome[J].Clin Chem,2006,52(3):405-413.
[6]	Xu A,Tso AW,Cheung BM,et al.Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome:a 5-year prospective study[J].Circulation,2007,115(12):1537-1543.
[7]	Nakamura R,Okura T,Fujioka Y,et al.Serum fatty acid-binding protein 4(FABP4)concentration is associated with insulin resistance in peripheral tissues,Aclinical study[J].PLoS One,2017,12(6):e0179737.
[8]	Tso AW,Xu A,Sham PC,et al.Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2diabetes:a 10-year prospective study in a Chinese cohort[J].Diabetes Care,2007,30:2667-2672.
[9]	Ota H,Furuhashi M,Ishimura S,et al.Elevation of fatty acid-binding protein 4is predisposed by family history of hypertension and contributes to blood pressure elevation[J].Am J Hypertens,2012,25(10):1124-1130.
[10]	CabréA,Lázaro I,Girona J,et al.Plasma fatty acid binding protein 4is associated with atherogenic dyslipidemia in diabetes[J].J Lipid Res,2008,49(8):1746-1751.
[11]	Yeung DC,Xu A,Cheung CW,et al.Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis[J].Arterioscler Thromb Vasc Biol,2007,27(8):1796-1802.
[12]	Fuseya T,Furuhashi M,Yuda S,et al.Elevation of circulating fatty acid-binding protein 4is independently associated with left ventricular diastolic dysfunction in a general population[J].Cardiovasc Diabetol,2014,13:126.
[13]	Rodríguez-Calvo R,Girona J,Alegret JM,et al.Role of the fatty acid-binding protein 4in heart failure and cardiovascular disease[J].J Endocrinol,2017,233(3):R173-R184.
[14]	Furuhashi M,Yuda S,Muranaka A,et al.Circulating fatty acid-binding protein 4concentration predicts the progression of carotid atherosclerosis in a general population without medication[J].Circ J,2018,82(4):1121-1129.
[15]	Peeters W,de Kleijn DP,Vink A,et al.Adipocyte fatty acid binding protein in atherosclerotic plaques is associated with local vulnerability and is predictive for the occurrence of adverse cardiovascular events[J].Eur Heart J,2011,32(14):1758-1768.
[16]	Reiser H,Klingenberg R,Hof D,et al.Circulating FABP4is a prognostic biomarker in patients with acute coronary syndrome but not in asymptomatic individuals[J].Arterioscler Thromb Vasc Biol,2015,35(8):1872-1879.
[17]	Furuhashi M,Tuncman G,G9rgün CZ,et al.Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2[J].Nature,2007,447(7147):959-965.
[18]	Furuhashi M,Hotamisligil GS.Fatty acid-binding proteins:role in metabolic diseases and potential as drug targets[J].Nat Rev Drug Discov,2008,7(6):489-503.
[19]	中国医师协会急诊医师分会.2015年急诊急性冠脉综合症临床实践指南[J].中国急救医学,2016,36(1):9-11.
[20]	宋峥,苏文,崔天盆,等.基于脂质代谢的体质特征与冠心病发生的关系研究[J].临床急诊杂志,2020,21(8):659-662.
[21]	Melki SA,Abumrad NA.Expression of the adipocyte fatty acid-binding protein in streptozotocin-diabetes:effects of insulin deficiency and supplementation[J].JLipid Res,1993,34(9):1527-1534.
[22]	Fu Y,Luo N,Lopes-Virella MF.Oxidized LDL induces the expression of ALBP/aP2 mRNA and protein in human THP-1 macrophages[J].J Lipid Res,2000,41(12):2017-2023.
[23]	Song J,Ren P,Zhang L,et al.Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4[J].Biochem Biophys Res Commun,2010,393(1):89-94.
[24]	Garin-Shkolnik T,Rudich A,Hotamisligil GS,et al.FABP4attenuates PPARγand adipogenesis and is inversely correlated with PPARγin adipose tissues[J].Diabetes,2014,63(3):900-911.
[25]	Mita T,Furuhashi M,Hiramitsu S,et al.FABP4is secreted from adipocytes by adenyl cyclase-PKA-and guanylyl cyclase-PKG-dependent lipolytic mechanisms[J].Obesity(Silver Spring),2015,23(2):359-367.
[26]	Lee K,Santibanez-Koref M,Polvikoski T,et al.Increased expression of fatty acid binding protein 4and leptin in resident macrophages characterises atherosclerotic plaque rupture[J].Atherosclerosis,2013,226(1):74-81.
[27]	Tuncman G,Hirosumi J,Solinas G,et al.Functional in vivo interactions between JNK1and JNK2isoforms in obesity and insulin resistance[J].Proc Natl Acad Sci USA,2006,103(28):10741-10746.
[28]	Furuhashi M,Tuncman G,G9rgün CZ,et al.Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2[J].Nature,2007,447(7147):959-965.
[29]	Makowski L,Boord JB,Maeda K,et al.Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis[J].Nat Med,2001,7(6):699-705.